AstraZeneca plc (AZN) Stock Rating Reaffirmed by JPMorgan Chase & Co.
JPMorgan Chase & Co. reaffirmed their neutral rating on shares of AstraZeneca plc (LON:AZN) in a report released on Monday. JPMorgan Chase & Co. currently has a GBX 4,900 ($63.96) price objective on the biopharmaceutical company’s stock.
A number of other research firms have also commented on AZN. Shore Capital reaffirmed a hold rating on shares of AstraZeneca plc in a research note on Thursday, June 23rd. Credit Suisse Group AG reaffirmed an underperform rating and issued a GBX 4,000 ($52.21) price objective on shares of AstraZeneca plc in a research note on Wednesday, July 13th. Citigroup Inc. reaffirmed a buy rating on shares of AstraZeneca plc in a research note on Friday, September 23rd. Goldman Sachs Group Inc. set a GBX 4,000 ($52.21) price objective on shares of AstraZeneca plc and gave the company a sell rating in a research note on Wednesday, June 29th. Finally, Jefferies Group upped their price objective on shares of AstraZeneca plc from GBX 4,800 ($62.66) to GBX 5,050 ($65.92) and gave the company a hold rating in a research note on Thursday, August 4th. Five investment analysts have rated the stock with a sell rating, fourteen have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. AstraZeneca plc presently has a consensus rating of Hold and an average price target of GBX 4,937.91 ($64.46).
Shares of AstraZeneca plc (LON:AZN) opened at 5026.00 on Monday. The company’s 50 day moving average is GBX 5,004.64 and its 200-day moving average is GBX 4,431.30. The firm’s market capitalization is GBX 63.58 billion. AstraZeneca plc has a one year low of GBX 3,680.00 and a one year high of GBX 5,505.00.
The firm also recently announced a dividend, which was paid on Monday, September 12th. Shareholders of record on Thursday, August 11th were given a dividend of GBX 68.70 ($0.90) per share. The ex-dividend date of this dividend was Thursday, August 11th. This represents a yield of 1.37%.
AstraZeneca plc Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.